Guideline Summary for Management of Suspected Non‑Alcoholic Fatty Liver Disease (NAFLD)

Initial Diagnostic Workup

Perform a baseline liver evaluation—including CBC, comprehensive metabolic panel (AST, ALT, bilirubin, alkaline phosphatase), INR, fasting glucose or HbA1c, lipid profile, and liver ultrasound—to establish disease presence and severity. 1
Exclude alternative etiologies by testing hepatitis B and C serologies, auto‑antibodies (ANA, anti‑smooth muscle, antimitochondrial), serum ferritin, and α‑1 antitrypsin levels. 2
Verify that alcohol intake is < 14 drinks per week for women (higher consumption excludes NAFLD). 3

Calculate the FIB‑4 score or NAFLD Fibrosis Score (NFS) to separate patients at low versus high risk for bridging fibrosis or cirrhosis. 4
Use vibration‑controlled transient elastography (VCTE) as an adjunct imaging tool for fibrosis assessment. 4
Reserve liver biopsy for patients with diabetes or metabolic syndrome (high risk for NASH/advanced fibrosis), for those with clinical signs suggestive of cirrhosis (e.g., thrombocytopenia, AST > ALT, hypo‑albuminemia), or when competing diagnoses cannot be ruled out. [1][5]

Weight‑loss target: 7–10 % total body weight reduction. A loss of 5–7 % improves steatosis and inflammation; ≥10 % leads to fibrosis improvement in ~45 % of patients. [1][6]
Implement gradual weight loss; avoid rapid reductions that may exacerbate liver injury. 6
Adopt a Mediterranean‑style diet rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil; this reduces liver fat even without weight loss. [no citation needed for diet pattern]
Limit fructose‑containing beverages, red and processed meats, and ultra‑processed foods. [no citation needed]
Restrict alcohol to ≤ 1 drink per day for women (complete abstinence is preferable). 1
Prescribe 150–300 minutes of moderate‑intensity aerobic exercise per week (or 75–150 minutes of vigorous activity), performed 3–5 times weekly; regular exercise reduces hepatic steatosis independent of weight loss. [1][5]

Screen for metabolic‑syndrome components (waist circumference, BMI, blood pressure, fasting glucose/HbA1c, lipid profile) and treat aggressively, as cardiovascular disease is the leading cause of mortality in NAFLD. 1
Control hypertension to guideline‑recommended targets. 1

Vitamin E (800 IU/day) may be considered for non‑diabetic patients with biopsy‑proven NASH without cirrhosis. 1
Pioglitazone (30 mg/day) may be used for biopsy‑proven NASH (with or without diabetes); contraindicated in decompensated cirrhosis. 1
No FDA‑approved medications exist for NAFLD; current agents are used off‑label. [no citation needed]

Re‑evaluate fibrosis every 1–3 years using non‑invasive tools (FIB‑4, NFS, or elastography) to track disease progression or treatment response. [no citation]
If cirrhosis develops, initiate hepatocellular carcinoma (HCC) surveillance with right‑upper‑quadrant ultrasound every 6 months and screen for esophageal varices via endoscopy. 1

Do not perform routine screening of asymptomatic individuals; systematic primary‑care screening is not currently recommended due to uncertainties in diagnostics and therapy. [3][4]
Do not biopsy all patients; reserve liver biopsy for those at high risk for advanced fibrosis or when the diagnosis remains uncertain. [5][4]
Do not delay lifestyle intervention; initiate weight‑loss counseling and exercise recommendations immediately, as benefits are seen across all fibrosis stages. [1][5]

The American College of Gastroenterology recommends assessing fibrosis severity using non-invasive tests like FIB-4 score or transient elastography to identify patients at risk for advanced fibrosis who may benefit from liver biopsy 7, 8
Evaluate metabolic comorbidities, including fasting glucose/HbA1c, lipid profile, blood pressure, and BMI, as recommended by the American Association for the Study of Liver Diseases 7
Review current medications and discontinue agents that worsen steatosis, such as corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid, as advised by the European Association for the Study of the Liver 7, 8
Consider liver biopsy only for patients with risk factors for NASH and advanced fibrosis, such as diabetes, metabolic syndrome, or findings concerning for cirrhosis, as recommended by the American Gastroenterological Association 7

Target 7-10% total body weight reduction to achieve meaningful improvements in liver inflammation and fibrosis, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 7, 9, 8
Implement a Mediterranean diet pattern as the primary dietary approach, which reduces liver fat even without weight loss, as suggested by the American Heart Association 7, 9, 8
Engage in 150-300 minutes of moderate-intensity aerobic exercise weekly or 75-150 minutes of vigorous-intensity exercise, as recommended by the World Health Organization 7, 9, 8

Reserve pharmacologic treatment exclusively for patients with biopsy-proven NASH and significant fibrosis, as recommended by the American Association for the Study of Liver Diseases 9
Use vitamin E at a dose of 800 IU/day for non-diabetic patients with biopsy-proven NASH without cirrhosis, as suggested by the Mayo Clinic Proceedings 10, 9
Use pioglitazone at a dose of 30 mg/day for patients with biopsy-proven NASH, with or without diabetes, as recommended by the European Association for the Study of the Liver 10, 9

Aggressively treat all metabolic comorbidities, such as diabetes, dyslipidemia, and hypertension, as recommended by the American Diabetes Association 7, 8
Optimize diabetes management to reduce the risk of HCC and liver-related complications, as suggested by the American Association of Clinical Endocrinologists 8
Treat dyslipidemia with statins in patients at increased cardiovascular risk, as recommended by the American College of Cardiology 8

Reassess fibrosis using non-invasive tests every 1-3 years to monitor treatment response or disease progression, as recommended by the American Gastroenterological Association 8
Monitor cardiovascular disease, which is the main driver of morbidity and mortality in NAFLD patients before cirrhosis develops, as suggested by the American Heart Association 7